nach oben

Erschienen in:

01.07.2015 | Original Article

[¹⁸F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study

verfasst von: Eliot T. McKinley, Jennifer M. Watchmaker, A. Bapsi Chakravarthy, Jeffrey A. Meyerhardt, Jeffrey A. Engelman, Ronald C. Walker, M. Kay Washington, Robert J. Coffey, H. Charles Manning

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Object

This pilot study evaluated the utility of 3′-deoxy-3′[18F]-fluorothymidine ([¹⁸F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers.

Methods

Baseline [¹⁸F]-FLT PET was collected prior to treatment initiation. Follow-up [¹⁸F]-FLT was collected after three weekly infusions of cetuximab, and following a combined regimen of cetuximab, 5-FU, and radiation. Imaging-matched biopsies were collected with each PET study.

Results

Diminished [¹⁸F]-FLT PET was observed in 3/4 of patients following cetuximab treatment alone and in all patients following combination therapy. Reduced [¹⁸F]-FLT PET following combination therapy predicted disease-free status at surgery. Overall, [¹⁸F]-FLT PET agreed with Ki67 immunoreactivity from biopsy samples and surgically resected tissue, and was predictive of treatment-induced rise in p27 levels.

Conclusion

These results suggest that [¹⁸F]-FLT PET is a promising imaging biomarker to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer.

Nur mit Berechtigung zugänglich

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334–6 Epub 1998/11/11.PubMedCrossRef

Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med. 2003;44(9):1432–4.PubMed

Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res. 2008;14(22):7413–22.PubMedCentralPubMedCrossRef

Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009;15(14):4712–21.PubMedCentralPubMedCrossRef

Kim SJ, Lee JS, Im KC, Kim SY, Park SA, Lee SJ, et al. Kinetic modeling of 3′-deoxy-3′-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. J Nucl Med. 2008;49(12):2057–66.PubMedCrossRef

Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714–21.PubMedCrossRef

McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R, Coffey RJ, et al. [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Menetrier’s disease. Ann Nucl Med. 2012;26(9):757–63.PubMedCentralPubMedCrossRef

Muzi M, Spence AM, O’Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47(10):1612–21.PubMed

10.

Soloviev D, Lewis D, Honess D, Aboagye E. [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48(4):416–24.PubMedCrossRef

11.

McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, et al. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One. 2013;8(3):e58938.PubMedCentralPubMedCrossRef

12.

Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q, et al. [(18)F]FLT-PET imaging does not always “light up” proliferating tumor cells. Clin Cancer Res. 2012;18(5):1303–12.PubMedCrossRef

13.

McKinley ET, Zhao P, Coffey RJ, Washington MK, Manning HC. 3′-Deoxy-3′-[18F]-Fluorothymidine PET imaging reflects PI3 K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PLoS One. 2014;9(9):e108193.PubMedCentralPubMedCrossRef

14.

Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med. 2010;51(10):1559–64.PubMedCrossRef

15.

Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin. 2007;28(9):1476–93.PubMedCrossRef

16.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–9.PubMedCrossRef

17.

Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol. 2005;23(36):9265–74.PubMedCrossRef

18.

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–8.PubMedCrossRef

19.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24(30):4914–21.PubMedCrossRef

20.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–7.PubMedCrossRef

21.

Oh SJ, Mosdzianowski C, Chi DY, Kim JY, Kang SH, Ryu JS, et al. Fully automated synthesis system of 3′-deoxy-3′-[18F]fluorothymidine. Nucl Med Biol. 2004;31(6):803–9.PubMedCrossRef

22.

Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2(5):146–58.PubMedCentralPubMedCrossRef

23.

Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13(1):74–84.PubMedCentralPubMedCrossRef

24.

Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012;7(4):e35309.PubMedCentralPubMedCrossRef

25.

O’Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25(24):3644–8.PubMedCrossRef

26.

Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006;20(11):1373–82 (discussion 82, 92–4, 97).

27.

Agool A, Slart RH, Thorp KK, Glaudemans AW, Cobben DC, Been LB, et al. Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F-FLT-PET study. Nucl Med Commun. 2011;32(1):17–22.PubMedCrossRef

28.

Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34(6):878–83.PubMedCrossRef

29.

Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron emission tomography with [(18)F]-3′-deoxy-3′fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol. 2013;15(1):106–13.PubMedCentralPubMedCrossRef

Titel: [18F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study
verfasst von: Eliot T. McKinley
Jennifer M. Watchmaker
A. Bapsi Chakravarthy
Jeffrey A. Meyerhardt
Jeffrey A. Engelman
Ronald C. Walker
M. Kay Washington
Robert J. Coffey
H. Charles Manning
Publikationsdatum: 01.07.2015
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 6/2015
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-015-0974-6

Springer Medizin

Abstract

Object

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Impact of residual 18F-fluoride in 18F-FDOPA for the diagnosis of neuroblastoma

Optimized production and quality control of 68Ga-EDTMP for small clinical trials

Ventilation/perfusion SPECT or SPECT/CT for lung function imaging in patients with pulmonary emphysema?

Role of 64CuCl2 PET/CT in staging of prostate cancer

Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors

Estimated human absorbed dose for 68Ga-ECC based on mice data: comparison with 67Ga-ECC